{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:50:38Z","timestamp":1791899438899,"version":"4.3.4"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T00:00:00Z","timestamp":1700784000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T00:00:00Z","timestamp":1700784000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Anhui Scientific Research and Innovation Team of Quality Evaluation and Improvement of Traditional Chinese Medicine","award":["2022AH010090"],"award-info":[{"award-number":["2022AH010090"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s13318-023-00867-z","type":"journal-article","created":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T16:02:15Z","timestamp":1700841735000},"page":"33-42","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Ticagrelor Steady-State Trough Concentration in Chinese Patients Undergoing Percutaneous Coronary Intervention"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0249-5524","authenticated-orcid":false,"given":"ShaoJun","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Jie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"NaiDong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"XiJing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YuBing","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,24]]},"reference":[{"issue":"9","key":"867_CR1","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1093\/eurheartj\/ehi754","volume":"27","author":"S Husted","year":"2006","unstructured":"Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J. 2006;27(9):1038\u201347. https:\/\/doi.org\/10.1093\/eurheartj\/ehi754.","journal-title":"Eur Heart J"},{"issue":"4","key":"867_CR2","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/j.1755-5922.2009-00096.x","volume":"27","author":"S Husted","year":"2009","unstructured":"Husted S, Giezen V. Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist. Cardiovasc Ther. 2009;27(4):259\u201374. https:\/\/doi.org\/10.1111\/j.1755-5922.2009-00096.x.","journal-title":"Cardiovasc Ther"},{"issue":"1","key":"867_CR3","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s40256-015-0108-5","volume":"15","author":"S Dhillon","year":"2015","unstructured":"Dhillon S. Ticagrelor: a review of its use in adults with acute coronary syndromes. Am J Cardiovasc Drugs. 2015;15(1):51\u201368. https:\/\/doi.org\/10.1007\/s40256-015-0108-5.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"11","key":"867_CR4","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","volume":"361","author":"L Wallentin","year":"2009","unstructured":"Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, et\u00a0al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045\u201357. https:\/\/doi.org\/10.1056\/NEJMoa0904327.","journal-title":"N Engl J Med"},{"issue":"5","key":"867_CR5","doi-asserted-by":"publisher","first-page":"305","DOI":"10.2165\/11630960-000000000-00000","volume":"51","author":"DR Teng","year":"2012","unstructured":"Teng DR. Pharmacokinetic, pharmacodynamic and pharmacogenetic profile of the oral antiplatelet agent ticagrelor. Clin Pharmacokinet. 2012;51(5):305\u201318. https:\/\/doi.org\/10.2165\/11630960-000000000-00000.","journal-title":"Clin Pharmacokinet"},{"key":"867_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.4528","volume":"33","author":"H Kelemen","year":"2019","unstructured":"Kelemen H, Hancu G, Papp LA. Analytical methodologies for the determination of ticagrelor. Biomed Chromatogr. 2019;33: e4528. https:\/\/doi.org\/10.1002\/bmc.4528.","journal-title":"Biomed Chromatogr"},{"issue":"2","key":"867_CR7","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2165\/11595930-000000000-00000","volume":"32","author":"H Li","year":"2012","unstructured":"Li H, Butler K, Yang L, Yang Z, Teng R. Pharmacokinetics and tolerability of single and multiple doses of ticagrelor in healthy Chinese subjects: an open-label, sequential, two-cohort, single-centre study. Clin Drug Investig. 2012;32(2):87\u201397. https:\/\/doi.org\/10.2165\/11595930-000000000-00000.","journal-title":"Clin Drug Investig"},{"issue":"9","key":"867_CR8","doi-asserted-by":"publisher","first-page":"666","DOI":"10.5414\/CP202549","volume":"54","author":"JG Li","year":"2016","unstructured":"Li JG, Tang WF, Storey RF, Husted S, Teng R. Population pharmaacokinetics of ticagrelor in patients with acute coronary syndromes. Int J Clin Pharmacol Ther. 2016;54(9):666\u201374. https:\/\/doi.org\/10.5414\/CP202549.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"5","key":"867_CR9","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s-11886-014-0485-4","volume":"16","author":"Y Jeong","year":"2014","unstructured":"Jeong Y. \u201cEast Asian paradox\u201d: challenge for the current antiplatelet strategy of \u201cone-guideline-fits-all races\u201d in acute coronary syndrome. Curr Cardiol Rep. 2014;16(5):485. https:\/\/doi.org\/10.1007\/s-11886-014-0485-4.","journal-title":"Curr Cardiol Rep"},{"issue":"10","key":"867_CR10","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/nrcardio.2014.104","volume":"11","author":"G Levine","year":"2014","unstructured":"Levine G, Jeong Y, Goto S, Anderson J, Huo Y, Mega J, Taubert K, Smith S. Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. Nat Rev Cardiol. 2014;11(10):597\u2013606. https:\/\/doi.org\/10.1038\/nrcardio.2014.104.","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"867_CR11","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1080\/09537104.2020.1732328","volume":"32","author":"J Shi","year":"2021","unstructured":"Shi J, He M, Wang W, Liu J, Zhang H, Sun D, Li J, Mu H, Xu M, Zhao C, Wang J, Zhang C, Cang H, Zhao S, Zhang Z, Li Y. Efficacy and safety of different ticagrelor regimens versus clopidogrel in patients with coronary artery disease: a retrospective multicenter study (SUPERIOR). Platelets. 2021;32(1):120\u20139. https:\/\/doi.org\/10.1080\/09537104.2020.1732328.","journal-title":"Platelets"},{"key":"867_CR12","doi-asserted-by":"publisher","first-page":"117954762095663","DOI":"10.1177\/1179547620956634","volume":"13","author":"A Krakowiak","year":"2020","unstructured":"Krakowiak A, Kuleta J, Plech I, Zarebinski M, Wojciechowska M, Wretowski D, Cudnoch-Jedrzejewska A. Ticagrelor-related severe dyspnoea: mechanisms, characteristic features, differential diagnosis and treatment. Clin Med Insights Case Rep. 2020;13:117954762095663. https:\/\/doi.org\/10.1177\/1179547620956634.","journal-title":"Clin Med Insights Case Rep."},{"key":"867_CR13","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1093\/eurheartj\/ehab741","volume":"13","author":"Y Han","year":"2021","unstructured":"Han Y. Chinese expert consensus statement on dual antiplatelet therapy in patients with coronary artery disease. Eur Heart J. 2021;13:1283\u20135. https:\/\/doi.org\/10.1093\/eurheartj\/ehab741.","journal-title":"Eur Heart J"},{"issue":"6","key":"867_CR14","doi-asserted-by":"publisher","first-page":"397","DOI":"10.2165\/11599830-000000000-00000","volume":"51","author":"SE Husted","year":"2012","unstructured":"Husted SE, Storey RF, Bliden K. Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease. Clin Pharmacokinet. 2012;51(6):397\u2013409.","journal-title":"Clin Pharmacokinet"},{"issue":"23","key":"867_CR15","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1161\/CIRCULATIO-NAHA.110.009449","volume":"123","author":"R Mehran","year":"2011","unstructured":"Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, Serebruany V, Valgimigli M, Vranckx P, Taggart D, Sabik JF, Cutlip DE, Krucoff MW, Ohman M, Steg PG, White H. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011;123(23):2736\u201347. https:\/\/doi.org\/10.1161\/CIRCULATIO-NAHA.110.009449.","journal-title":"Circulation"},{"issue":"22","key":"867_CR16","first-page":"98","volume":"6","author":"Cardiovascular Laboratory Medicine Professional Committee of Laboratory Physicians Branch of Chinese Medical Doctor Association","year":"2018","unstructured":"Cardiovascular Laboratory Medicine Professional Committee of Laboratory Physicians Branch of Chinese Medical Doctor Association. Expert consensus on the application of platelet function detection in antiplatelet therapy in patients with acute coronary syndrome. Natl Med J China. 2018;6(22):98.","journal-title":"Natl Med J China."},{"issue":"4","key":"867_CR17","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1007\/s12928-014-0277-1","volume":"29","author":"Y Hiasa","year":"2014","unstructured":"Hiasa Y, Teng R, Emanuelsson H. Pharmacodynamics, pharmacokinetics and safety of ticagrelor in Asian patients with stable coronary artery disease. Cardiovasc Interv Ther. 2014;29(4):324\u201333. https:\/\/doi.org\/10.1007\/s12928-014-0277-1.","journal-title":"Cardiovasc Interv Ther"},{"key":"867_CR18","unstructured":"Wang HX. The effective concentration range of lamotrigine in epilepsy patients. Chin J Clin Pharmacol. 2019;35(1):4."},{"key":"867_CR19","doi-asserted-by":"publisher","DOI":"10.1080\/14656566-2017.1421634","author":"D Danielak","year":"2017","unstructured":"Danielak D, Kara\u017aniewicz-\u0141ada M, G\u0142\u00f3wka F. Ticagrelor in modern cardiology an up-to-date review of most important aspects of ticagrelor pharmacotherapy. Expert Opin Pharmacother. 2017. https:\/\/doi.org\/10.1080\/14656566-2017.1421634.","journal-title":"Expert Opin Pharmacother"},{"issue":"9","key":"867_CR20","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1177\/0091270011415526","volume":"52","author":"K Butler","year":"2013","unstructured":"Butler K, Teng R. Pharmacokinetics, pharmacodynamics, and safety of ticagrelor in volunteers with severe renal impairment. J Clin Pharmacol. 2013;52(9):75\u20138. https:\/\/doi.org\/10.1177\/0091270011415526.","journal-title":"J Clin Pharmacol"},{"issue":"19","key":"867_CR21","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1016\/j.jacc.2019.03.470","volume":"73","author":"S Arora","year":"2019","unstructured":"Arora S, Shemisa K, Vaduganathan M, Qamar A, Gupta A, Garg SK, Kumbhani DJ, Mayo H, Khalili H, Pandey A, Das SR. Premature ticagrelor discontinuation in secondary prevention of atherosclerotic CVD: JACC review topic of the week. J Am Coll Cardiol. 2019;73(19):2454\u201364. https:\/\/doi.org\/10.1016\/j.jacc.2019.03.470.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"867_CR22","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1016\/j.amjcard.2007.06.026","volume":"100","author":"F Feit","year":"2007","unstructured":"Feit F, Voeltz MD, Attubato MJ, Lincoff AM, Chew DP, Bittl JA, Topol EJ, Manoukian SV. Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2Trial. Am J Cardiol. 2007;100(9):1364\u20139. https:\/\/doi.org\/10.1016\/j.amjcard.2007.06.026.","journal-title":"Am J Cardiol"},{"issue":"1","key":"867_CR23","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3109\/2155-6660.2013.785413","volume":"2","author":"R Teng","year":"2013","unstructured":"Teng R, Butler K. Effect of the CYP3A inhibitors, diltiazem and ketoconazole, on ticagrelor pharmacokinetics in healthy volunteers. J Drug Assess. 2013;2(1):30\u20139. https:\/\/doi.org\/10.3109\/2155-6660.2013.785413.","journal-title":"J Drug Assess."}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-023-00867-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-023-00867-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-023-00867-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T18:13:07Z","timestamp":1704910387000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-023-00867-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,24]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["867"],"URL":"https:\/\/doi.org\/10.1007\/s13318-023-00867-z","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,24]]},"assertion":[{"value":"1 November 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Anhui Scientific Research and Innovation Team of Quality Evaluation and Improvement of Traditional Chinese Medicine (2022AH010090).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The author(s) declare no potential conflicts of interest with respect to the research, authorship, and\/or publication of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Ethics Committee of Nanjing First Hospital approved the study protocol (approval number KY2019530-05). The study was conducted in accordance with the International Conference on Harmonisation Guideline for Good Clinical Practice and the Declaration of Helsinki.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All subjects provided written informed consent before participation","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets used and\/or analyzed during the current study are available from the corresponding author upon reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"SZ was responsible for conception and design, data collection, interpretation of the data, drafting of the article, final approval of the manuscript, and statistical analysis; QJ and NC for interpretation of the data and data collection; and YZ and XC for conception and design, final approval of the manuscript, and supervision. Each author contributed important intellectual content during manuscript drafting or revision and accepts accountability for the overall work by ensuring that questions pertaining to the accuracy or integrity of any portion of the work are appropriately investigated and resolved.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors Contributions"}}]}}